817 related articles for article (PubMed ID: 28412319)
21. Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism.
Vandell AG; Walker J; Brown KS; Zhang G; Lin M; Grosso MA; Mercuri MF
Heart; 2017 Nov; 103(22):1800-1805. PubMed ID: 28689179
[TBL] [Abstract][Full Text] [Related]
22. The rs2108622 polymorphism is related to the early risk of ischemic stroke in non-valvular atrial fibrillation subjects under oral anticoagulation.
Colàs-Campàs L; Royo JL; Montserrat MV; Marzo C; Molina-Seguín J; Benabdelhak I; Cambray S; Purroy F
Pharmacogenomics J; 2018 Sep; 18(5):652-656. PubMed ID: 29273767
[TBL] [Abstract][Full Text] [Related]
23. CYP2C9 Polymorphism and Unstable Anticoagulation with Warfarin in Patients Within the First 3 Months Following Heart Valve Replacement.
Wypasek E; Cieśla M; Suder B; Janik Ł; Sadowski J; Undas A
Adv Clin Exp Med; 2015; 24(4):607-14. PubMed ID: 26469104
[TBL] [Abstract][Full Text] [Related]
24. VKORC1 gene polymorphisms and adverse events in Croatian patients on warfarin therapy.
Mandic D; Bozina N; Mandic S; Samardzija M; Milostic-Srb A; Rumora L
Int J Clin Pharmacol Ther; 2015 Nov; 53(11):905-13. PubMed ID: 26445138
[TBL] [Abstract][Full Text] [Related]
25. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients.
Gallagher AM; Setakis E; Plumb JM; Clemens A; van Staa TP
Thromb Haemost; 2011 Nov; 106(5):968-77. PubMed ID: 21901239
[TBL] [Abstract][Full Text] [Related]
26. Improving Anticoagulation Measurement Novel Warfarin Composite Measure.
Razouki Z; Burgess JF; Ozonoff A; Zhao S; Berlowitz D; Rose AJ
Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):600-7. PubMed ID: 26420820
[TBL] [Abstract][Full Text] [Related]
27. Predictors of warfarin dose requirements in South African patients attending an anticoagulation clinic.
Schapkaitz E; Sithole J
J Vasc Nurs; 2017 Mar; 35(1):27-30. PubMed ID: 28224948
[TBL] [Abstract][Full Text] [Related]
28. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
[TBL] [Abstract][Full Text] [Related]
29. Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves.
An SH; Chang BC; Lee KE; Gwak HS
Cardiovasc Ther; 2015 Dec; 33(6):324-8. PubMed ID: 26223945
[TBL] [Abstract][Full Text] [Related]
30. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
[TBL] [Abstract][Full Text] [Related]
31. Quality of oral anticoagulation control in Chinese patients with non-valvular atrial fibrillation: a prospective controlled study.
Li Y; Yu J; Kuang Y; Wu C; Yang L; Fang Q; Pei Q; Yang G
Curr Med Res Opin; 2020 Sep; 36(9):1433-1439. PubMed ID: 32677855
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the impact of warfarin time in therapeutic range on outcomes of patients with atrial fibrillation in Turkey: perspectives from the observational, prospective WATER Registry.
Turk UO; Tuncer E; Alioglu E; Yuksel K; Pekel N; Ozpelit E; Vuran O; Tengiz I
Cardiol J; 2015; 22(5):567-75. PubMed ID: 26100825
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness and safety of dabigatran versus acenocoumarol in 'real-world' patients with atrial fibrillation.
Korenstra J; Wijtvliet EP; Veeger NJ; Geluk CA; Bartels GL; Posma JL; Piersma-Wichers M; Van Gelder IC; Rienstra M; Tieleman RG
Europace; 2016 Sep; 18(9):1319-27. PubMed ID: 26843571
[TBL] [Abstract][Full Text] [Related]
34. Preliminary outcomes of preemptive warfarin pharmacogenetic testing at a large rural healthcare center.
Leary E; Brilliant M; Peissig P; Griesbach S
Am J Health Syst Pharm; 2019 Feb; 76(6):387-397. PubMed ID: 31415684
[TBL] [Abstract][Full Text] [Related]
35. [Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in Moscow population: effects on stability of anticoagulant therapy and frequency of hemorrhage].
Vorob'eva NM; Panchenko EP; Dobrovol'skiĭ AB; Titaeva EV; Khasanova ZB; Konovalova NV; Postnov AIu; Kirienko AI
Ter Arkh; 2011; 83(6):59-65. PubMed ID: 21786578
[TBL] [Abstract][Full Text] [Related]
36. Non-genetic factors and polymorphisms in genes CYP2C9 and VKORC1: predictive algorithms for TTR in Brazilian patients on warfarin.
Praxedes MFS; Martins MAP; Mourão AOM; Gomes KB; Reis EA; Souza RP; Campos EIF; Ribeiro DD; Rocha MOC
Eur J Clin Pharmacol; 2020 Feb; 76(2):199-209. PubMed ID: 31720756
[TBL] [Abstract][Full Text] [Related]
37. Randomized controlled trial of genotype-guided warfarin anticoagulation in Chinese elderly patients with nonvalvular atrial fibrillation.
Zhu Y; Xu C; Liu J
J Clin Pharm Ther; 2020 Dec; 45(6):1466-1473. PubMed ID: 32710457
[TBL] [Abstract][Full Text] [Related]
38. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Mega JL; Walker JR; Ruff CT; Vandell AG; Nordio F; Deenadayalu N; Murphy SA; Lee J; Mercuri MF; Giugliano RP; Antman EM; Braunwald E; Sabatine MS
Lancet; 2015 Jun; 385(9984):2280-7. PubMed ID: 25769357
[TBL] [Abstract][Full Text] [Related]
39. Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione.
Lacut K; Ayme-Dietrich E; Gourhant L; Poulhazan E; Andro M; Becquemont L; Mottier D; Le Gal G; Verstuyft C
Br J Clin Pharmacol; 2012 Mar; 73(3):428-36. PubMed ID: 21883387
[TBL] [Abstract][Full Text] [Related]
40. Integrated analysis of clinical and genetic factors on the interindividual variation of warfarin anticoagulation efficacy in clinical practice.
Sun B; Ma S; Xiao F; Luo J; Liu M; Liu W; Luo Z
BMC Cardiovasc Disord; 2023 May; 23(1):279. PubMed ID: 37254053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
